» Articles » PMID: 30150099

Comparison Between COPD Assessment Test (CAT) and Modified Medical Research Council (mMRC) Dyspnea Scores for Evaluation of Clinical Symptoms, Comorbidities and Medical Resources Utilization in COPD Patients

Overview
Specialty General Medicine
Date 2018 Aug 29
PMID 30150099
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposed a new severity assessment system for emphasizing clinical symptom evaluation by COPD Assessment Test (CAT) or modified Medical Research Council (mMRC) dyspnea scores. The aim of the study was to evaluate the effectiveness of two scoring systems in evaluating COPD patients.

Methods: A population based cross-sectional study employing computer-assisted telephone interviewing system (CATI) for surveying the epidemiology of COPD in Taiwan. Among 6600 subjects recruited (age > 40), 404 subjects (6.1%) were diagnosed as COPD. The comorbidities, COPD-related symptoms, health care resources utilization were compared between CAT and mMRC.

Results: There were significant differences in all co-morbidities, symptom severity in favor of CAT as compared to mMRC. When comparing health care resources utilization, CAT and mMRC have equal effectiveness in evaluating patients with regular medical treatment. There were significant differences in emergency room visit and hospitalization in favor of mMRC. However, CAT was more effective in evaluating patients with ICU admission (P = 0.005).

Conclusion: Compared with CAT and mMRC, there are individual benefits in the evaluation of clinical symptoms, co-morbidities and medical resources utilization for ER, hospitalization and ICU admission in COPD patients.

Citing Articles

The treatment responses among different inhalation therapies for GOLD group E patients with chronic obstructive pulmonary disease.

Song Q, Lin L, Li T, Zhang P, Zeng Y, Deng D J Glob Health. 2025; 15:04055.

PMID: 39977672 PMC: 11842004. DOI: 10.7189/jogh.15.04055.


Significance of serum lncRNA XIST in chronic obstructive pulmonary disease and its progression to pulmonary heart disease.

Huang X, Liang J, Li Y, Wei M, Liu Q, Jiang Y BMC Pulm Med. 2024; 24(1):546.

PMID: 39482714 PMC: 11526528. DOI: 10.1186/s12890-024-03354-6.


Investigating the Utility of Red Blood Cell Distribution Width as a Prognostic Indicator for Deterioration of Patients with Chronic Obstructive Pulmonary Disease Within One Year.

Liu Q, Wu K, Lin X, Xiang K, Wang J Int J Gen Med. 2024; 17:3869-3877.

PMID: 39263590 PMC: 11387594. DOI: 10.2147/IJGM.S469209.


Extracellular Water Ratio and Phase Angle as Predictors of Exacerbation in Chronic Obstructive Pulmonary Disease.

Xie A, Huang W, Ko C Adv Respir Med. 2024; 92(3):230-240.

PMID: 38921062 PMC: 11200775. DOI: 10.3390/arm92030023.


The use of antibiotics in the early stage of acute exacerbation of chronic obstructive pulmonary disease in patients without obvious signs of infection: a multicenter, randomized, parallel-controlled study.

Zhou L, Deng Y, Liu K, Liu H, Liu W Front Pharmacol. 2024; 15:1380939.

PMID: 38799157 PMC: 11116691. DOI: 10.3389/fphar.2024.1380939.